CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LRRC37BP1 (ImmuneEditome ID:147172)

1. Gene summary of enriched editing regions for LRRC37BP1

check button Gene summary
Gene informationGene symbol

LRRC37BP1

Gene ID

147172

GeneSynonymsLRRC37B2
GeneCytomap

17q11.2

GeneTypepseudo
GeneDescriptionLRRC37B pseudogene 1|leucine rich repeat containing 37, member B2|putative LRRC37B-like protein 2
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:30635215-30637852:+ENST00000398851.6ENSG00000250462.7LRRC37BP1ncRNA_exonicL1M5,AluJr,MER2,AluJr4,AluJb,AluSz6,AluYchr17:30635215-30637852:+.alignment
chr17:30635215-30637852:+ENST00000417404.2ENSG00000250462.7LRRC37BP1ncRNA_exonicL1M5,AluJr,MER2,AluJr4,AluJb,AluSz6,AluYchr17:30635215-30637852:+.alignment


Top

2. Tumor-specific enriched editing regions for LRRC37BP1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:30635215-30637852:+BRCAEER4.9543e-03image
ENSG00000250462.7,LRRC37BP1BRCAEAG4.0808e-03image
chr17:30635215-30637852:+KIRCEER4.7681e-02image
ENSG00000250462.7,LRRC37BP1KIRCEAG4.7791e-02image
chr17:30635215-30637852:+LUADEER1.3214e-02image
ENSG00000250462.7,LRRC37BP1LUADEAG1.3312e-02image
chr17:30635215-30637852:+LUSCEER8.7846e-03image
ENSG00000250462.7,LRRC37BP1LUSCEAG9.3829e-03image
chr17:30635215-30637852:+THCAEER2.1551e-02image
ENSG00000250462.7,LRRC37BP1THCAEAG2.1551e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000250462.7,LRRC37BP1KIRCPathEAG7.0049e-044.7172e-050.1833image
chr17:30635215-30637852:+KIRCPathEER7.0524e-044.7563e-050.1832image
ENSG00000250462.7,LRRC37BP1KIRPPathEAG1.9719e-024.6811e-020.1440image
chr17:30635215-30637852:+THCAPathEER3.2242e-024.5016e-030.1297image
ENSG00000250462.7,LRRC37BP1THCAPathEAG3.2242e-024.5016e-030.1297image
chr17:30635215-30637852:+UCECCliEER3.7273e-026.5390e-03-0.2411image
ENSG00000250462.7,LRRC37BP1UCECCliEAG3.9354e-027.0020e-03-0.2382image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr17:30635215-30637852:+UCECEER6.6473e-052.9556e-035.0323e+04image
ENSG00000250462.7,LRRC37BP1UCECEAG6.6473e-052.9556e-035.0323e+04image

Top

3. Enriched editing regions and immune related genes for LRRC37BP1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:30635215-30637852:+ESCAEERENSG00000027869,SH2D2A0.43034.6784e-041.1333e-080.4686imageNDKC1;FUS;TARDBP;TROVE2;U2AF2NAT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:30635215-30637852:+ESCAEERENSG00000152102,FAM168B-0.42456.4856e-041.5287e-06-0.4014imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:30635215-30637852:+ESCAEERENSG00000166710,B2M0.38042.8888e-039.8490e-070.4081imageNDHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2B2MT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:30635215-30637852:+THYMEERENSG00000126883,NUP214-0.54681.6935e-065.8910e-09-0.5394imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NUP214T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000136861,CDK5RAP2-0.54762.0993e-064.7247e-10-0.5705imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAMacrophages_M1GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000172534,HCFC1-0.54682.2940e-063.3789e-08-0.5158imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2HCFC1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr17:30635215-30637852:+THYMEERENSG00000072736,NFATC3-0.52304.2536e-064.5787e-08-0.5115imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NFATC3T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000197471,SPN-0.51776.5292e-061.0544e-07-0.4995imageNADAR;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2SPNT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000107362,ABHD17B-0.51636.7630e-066.0483e-08-0.5076imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000102974,CTCF-0.52747.7249e-068.2346e-08-0.5031imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;U2AF2CTCFT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+ESCAEERENSG00000027869,SH2D2A0.43034.6784e-041.1333e-080.4686imageNDKC1;FUS;TARDBP;TROVE2;U2AF2NAT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:30635215-30637852:+ESCAEERENSG00000152102,FAM168B-0.42456.4856e-041.5287e-06-0.4014imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:30635215-30637852:+ESCAEERENSG00000166710,B2M0.38042.8888e-039.8490e-070.4081imageNDHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2B2MT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:30635215-30637852:+THYMEERENSG00000126883,NUP214-0.54681.6935e-065.8910e-09-0.5394imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NUP214T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000136861,CDK5RAP2-0.54762.0993e-064.7247e-10-0.5705imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAMacrophages_M1GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000172534,HCFC1-0.54682.2940e-063.3789e-08-0.5158imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2HCFC1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr17:30635215-30637852:+THYMEERENSG00000072736,NFATC3-0.52304.2536e-064.5787e-08-0.5115imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NFATC3T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000197471,SPN-0.51776.5292e-061.0544e-07-0.4995imageNADAR;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2SPNT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000107362,ABHD17B-0.51636.7630e-066.0483e-08-0.5076imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:30635215-30637852:+THYMEERENSG00000102974,CTCF-0.52747.7249e-068.2346e-08-0.5031imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;U2AF2CTCFT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT

More results



Top

4. Enriched editing regions and immune related splicing for LRRC37BP1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:30635215-30637852:+
ESCAEERA3ENSG00000105193.4chr1939433664:39433702:39433222:39433545:39433222:39433558-0.34711.3702e-024.2399e-08-0.4630imageNADAR;DHX9;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000250462.7,LRRC37BP1
ESCAEAGA3ENSG00000105193.4chr1939433664:39433702:39433222:39433545:39433222:39433558-0.33152.7600e-021.8772e-07-0.4427imageNNNADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000250462.7,LRRC37BP1
ESCAEAGA3ENSG00000082497.7chr1210239492:210239608:210245799:210245927:210241557:2102459270.34081.1610e-021.7646e-060.4393imageNNNAMast_cells_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr17:30635215-30637852:+
ESCAEERA3ENSG00000082497.7chr1210239492:210239608:210245799:210245927:210241557:2102459270.35904.7485e-037.2894e-070.4536imageNADAR;DKC1;FUS;NOP56;U2AF2NAMast_cells_restingGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000250462.7,LRRC37BP1
KIRPEAGMEXENSG00000185049.8chr41989707:1989869:1991543:1991709:2006997:2007199:2008749:2008835-0.29331.3870e-032.3007e-14-0.4948imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000250462.7,LRRC37BP1
KIRPEAGMEXENSG00000185049.8chr41989707:1989869:1991543:1991730:2006997:2007199:2008749:2008835-0.29321.3959e-031.1017e-14-0.5000imageNNNAMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000250462.7,LRRC37BP1
PCPGEAGA5ENSG00000204463.8chr631651655:31651776:31652512:31652648:31652399:316526480.30273.8977e-029.9112e-060.4008imageNNBAG6MonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr17:30635215-30637852:+
PCPGEERA5ENSG00000204463.8chr631651655:31651776:31652512:31652648:31652399:316526480.30274.1725e-029.9112e-060.4008imageNADAR;DKC1;FUS;NOP56;TARDBP;TROVE2;U2AF2BAG6MonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000250462.7,LRRC37BP1
THYMEAGMEXENSG00000149657.15chr2062124616:62124780:62126339:62126439:62129808:62129952:62130529:62130605-0.32071.5875e-022.0113e-05-0.4546imageNNLSM14BMast_cells_restingGSVA_HALLMARK_E2F_TARGETS
ENSG00000250462.7,LRRC37BP1
THYMEAGA5ENSG00000109113.13chr1728717212:28717291:28718369:28718405:28718121:28718405-0.40152.9227e-033.6733e-05-0.4184imageNNRAB34T_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

More results



Top

5. Enriched editing regions and immune infiltration for LRRC37BP1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:30635215-30637852:+BLCAEERMast_cells_resting1.9828e-04-0.2489image
ENSG00000250462.7,LRRC37BP1BLCAEAGMast_cells_resting1.9828e-04-0.2489image
chr17:30635215-30637852:+BRCAEERT_cells_regulatory_(Tregs)9.8647e-050.1298image
ENSG00000250462.7,LRRC37BP1BRCAEAGT_cells_regulatory_(Tregs)3.3860e-040.1195image
chr17:30635215-30637852:+CHOLEERNK_cells_activated3.7763e-020.4263image
ENSG00000250462.7,LRRC37BP1CHOLEAGNK_cells_activated3.7763e-020.4263image
ENSG00000250462.7,LRRC37BP1COADEAGT_cells_CD81.6495e-020.2405image
chr17:30635215-30637852:+ESCAEERT_cells_regulatory_(Tregs)1.9233e-02-0.2020image
ENSG00000250462.7,LRRC37BP1ESCAEAGT_cells_regulatory_(Tregs)1.5872e-02-0.2080image
chr17:30635215-30637852:+GBMEERPlasma_cells3.4763e-030.2312image
ENSG00000250462.7,LRRC37BP1GBMEAGPlasma_cells3.4763e-030.2312image
chr17:30635215-30637852:+HNSCEERMast_cells_activated1.8787e-030.2089image
ENSG00000250462.7,LRRC37BP1HNSCEAGMast_cells_activated1.8787e-030.2089image
chr17:30635215-30637852:+KIRCEERT_cells_CD4_memory_activated1.7677e-030.1654image
ENSG00000250462.7,LRRC37BP1KIRCEAGT_cells_CD4_memory_activated1.7606e-030.1655image
chr17:30635215-30637852:+KIRPEERT_cells_CD4_memory_resting8.1720e-03-0.1825image
ENSG00000250462.7,LRRC37BP1KIRPEAGT_cells_CD4_memory_resting3.1139e-02-0.1488image
ENSG00000250462.7,LRRC37BP1LAMLEAGT_cells_gamma_delta2.5581e-020.2858image
chr17:30635215-30637852:+LGGEERT_cells_CD4_memory_activated3.6012e-030.1276image
ENSG00000250462.7,LRRC37BP1LGGEAGT_cells_CD4_memory_activated3.6012e-030.1276image
chr17:30635215-30637852:+LUSCEERDendritic_cells_activated5.5125e-040.1878image
ENSG00000250462.7,LRRC37BP1LUSCEAGDendritic_cells_activated4.8158e-040.1897image
ENSG00000250462.7,LRRC37BP1MESOEAGMast_cells_resting1.0103e-02-0.3537image
chr17:30635215-30637852:+OVEERMacrophages_M11.0370e-020.1944image
ENSG00000250462.7,LRRC37BP1OVEAGMacrophages_M16.7332e-030.2041image
chr17:30635215-30637852:+PCPGEERMast_cells_resting1.2632e-02-0.2174image
ENSG00000250462.7,LRRC37BP1PCPGEAGMast_cells_resting1.2632e-02-0.2174image
chr17:30635215-30637852:+PRADEERDendritic_cells_activated1.2730e-040.1848image
ENSG00000250462.7,LRRC37BP1PRADEAGDendritic_cells_activated1.2419e-040.1851image
ENSG00000250462.7,LRRC37BP1READEAGT_cells_gamma_delta1.6695e-020.3964image
chr17:30635215-30637852:+SARCEERMacrophages_M29.2026e-030.1866image
ENSG00000250462.7,LRRC37BP1SARCEAGMacrophages_M29.2026e-030.1866image
chr17:30635215-30637852:+SKCMEERT_cells_CD89.5530e-040.1771image
ENSG00000250462.7,LRRC37BP1SKCMEAGT_cells_CD89.5530e-040.1771image
chr17:30635215-30637852:+STADEERT_cells_gamma_delta1.3094e-020.1714image
ENSG00000250462.7,LRRC37BP1STADEAGT_cells_gamma_delta8.7225e-030.1823image
ENSG00000250462.7,LRRC37BP1TGCTEAGT_cells_gamma_delta2.3162e-020.2521image
chr17:30635215-30637852:+THCAEERB_cells_naive5.6481e-050.1827image
ENSG00000250462.7,LRRC37BP1THCAEAGB_cells_naive5.6481e-050.1827image
chr17:30635215-30637852:+THYMEERMacrophages_M11.5386e-050.4157image
ENSG00000250462.7,LRRC37BP1THYMEAGMacrophages_M11.5386e-050.4157image
chr17:30635215-30637852:+UCECEERT_cells_CD81.4908e-020.2275image
ENSG00000250462.7,LRRC37BP1UCECEAGT_cells_CD82.1098e-020.2149image
chr17:30635215-30637852:+UCSEERMast_cells_activated3.5886e-070.6872image
ENSG00000250462.7,LRRC37BP1UCSEAGMast_cells_activated3.5886e-070.6872image
ENSG00000250462.7,LRRC37BP1UVMEAGPlasma_cells2.7510e-020.4240image


Top

6. Enriched editing regions and immune gene sets for LRRC37BP1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr17:30635215-30637852:+BLCAEER2.4296e-030.20394.1951e-020.13763.1809e-040.24106.2073e-040.2295image
ENSG00000250462.7,LRRC37BP1BLCAEAG2.4296e-030.20394.1951e-020.13763.1809e-040.24106.2073e-040.2295image
chr17:30635215-30637852:+LIHCEER2.8166e-02-0.20473.4465e-02-0.19741.5524e-02-0.22523.2597e-02-0.1995image
ENSG00000250462.7,LRRC37BP1LIHCEAG2.8166e-02-0.20473.4465e-02-0.19741.5524e-02-0.22523.2597e-02-0.1995image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:30635215-30637852:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.6419e-050.2867image
ENSG00000250462.7,LRRC37BP1BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6419e-050.2867image
ENSG00000250462.7,LRRC37BP1BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3485e-060.1546image
chr17:30635215-30637852:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.4419e-070.1694image
ENSG00000250462.7,LRRC37BP1CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.7496e-03-0.1929image
chr17:30635215-30637852:+CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.7496e-03-0.1929image
ENSG00000250462.7,LRRC37BP1CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.4858e-030.5885image
chr17:30635215-30637852:+CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER2.4858e-030.5885image
ENSG00000250462.7,LRRC37BP1COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1231e-020.2538image
chr17:30635215-30637852:+ESCAGSVA_HALLMARK_SPERMATOGENESISEER2.9308e-03-0.2551image
ENSG00000250462.7,LRRC37BP1ESCAGSVA_HALLMARK_SPERMATOGENESISEAG2.4119e-03-0.2600image
ENSG00000250462.7,LRRC37BP1GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.1729e-030.2097image
chr17:30635215-30637852:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1729e-030.2097image
chr17:30635215-30637852:+HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2044e-04-0.2569image
ENSG00000250462.7,LRRC37BP1HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.2044e-04-0.2569image
chr17:30635215-30637852:+KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.9650e-050.2136image
ENSG00000250462.7,LRRC37BP1KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.9781e-050.2136image
ENSG00000250462.7,LRRC37BP1KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.9853e-04-0.2421image
chr17:30635215-30637852:+KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.5725e-050.2666image
ENSG00000250462.7,LRRC37BP1LAMLGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.2834e-02-0.3169image
chr17:30635215-30637852:+LGGGSVA_HALLMARK_MYOGENESISEER1.1278e-070.2303image
ENSG00000250462.7,LRRC37BP1LGGGSVA_HALLMARK_MYOGENESISEAG1.1278e-070.2303image
chr17:30635215-30637852:+LIHCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.5594e-03-0.2697image
ENSG00000250462.7,LRRC37BP1LIHCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.5594e-03-0.2697image
chr17:30635215-30637852:+LUADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.6148e-020.1248image
ENSG00000250462.7,LRRC37BP1LUADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.6187e-020.1248image
ENSG00000250462.7,LRRC37BP1LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.2572e-03-0.1558image
chr17:30635215-30637852:+LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.4769e-03-0.1549image
ENSG00000250462.7,LRRC37BP1MESOGSVA_HALLMARK_KRAS_SIGNALING_UPEAG1.3256e-020.3414image
chr17:30635215-30637852:+OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER9.8928e-04-0.2483image
ENSG00000250462.7,LRRC37BP1OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.1384e-03-0.2440image
chr17:30635215-30637852:+PAADGSVA_HALLMARK_NOTCH_SIGNALINGEER4.2221e-020.1968image
ENSG00000250462.7,LRRC37BP1PAADGSVA_HALLMARK_NOTCH_SIGNALINGEAG4.2221e-020.1968image
ENSG00000250462.7,LRRC37BP1PCPGGSVA_HALLMARK_MYC_TARGETS_V1EAG6.1130e-04-0.2955image
chr17:30635215-30637852:+PCPGGSVA_HALLMARK_MYC_TARGETS_V1EER6.1130e-04-0.2955image
chr17:30635215-30637852:+PRADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.9384e-04-0.1798image
ENSG00000250462.7,LRRC37BP1PRADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.6534e-04-0.1817image
ENSG00000250462.7,LRRC37BP1READGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.8109e-040.5704image
ENSG00000250462.7,LRRC37BP1SARCGSVA_HALLMARK_COMPLEMENTEAG4.4711e-040.2497image
chr17:30635215-30637852:+SARCGSVA_HALLMARK_COMPLEMENTEER4.4711e-040.2497image
chr17:30635215-30637852:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7369e-060.2541image
ENSG00000250462.7,LRRC37BP1SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7369e-060.2541image
chr17:30635215-30637852:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2114e-030.2106image
ENSG00000250462.7,LRRC37BP1STADGSVA_HALLMARK_MYC_TARGETS_V1EAG3.9845e-040.2444image
ENSG00000250462.7,LRRC37BP1TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.1956e-020.2266image
ENSG00000250462.7,LRRC37BP1THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.0375e-110.2972image
chr17:30635215-30637852:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.0375e-110.2972image
chr17:30635215-30637852:+THYMGSVA_HALLMARK_G2M_CHECKPOINTEER8.1467e-06-0.4277image
ENSG00000250462.7,LRRC37BP1THYMGSVA_HALLMARK_G2M_CHECKPOINTEAG8.1467e-06-0.4277image
chr17:30635215-30637852:+UCECGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER2.2046e-030.2839image
ENSG00000250462.7,LRRC37BP1UCECGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.3986e-030.2804image


Top

7. Enriched editing regions and drugs for LRRC37BP1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:30635215-30637852:+ACCATRAEER6.3994e-030.4650image
ENSG00000250462.7,LRRC37BP1ACCATRAEAG6.3994e-030.4650image
chr17:30635215-30637852:+BLCAEHT.1864EER5.7586e-070.3302image
ENSG00000250462.7,LRRC37BP1BLCAEHT.1864EAG5.7586e-070.3302image
ENSG00000250462.7,LRRC37BP1BRCACyclopamineEAG1.2378e-04-0.1282image
chr17:30635215-30637852:+BRCACGP.082996EER4.7098e-05-0.1356image
ENSG00000250462.7,LRRC37BP1CESCCI.1040EAG4.4833e-02-0.1435image
chr17:30635215-30637852:+CESCCI.1040EER4.4833e-02-0.1435image
ENSG00000250462.7,LRRC37BP1CHOLAMG.706EAG1.5946e-030.6088image
chr17:30635215-30637852:+CHOLAMG.706EER1.5946e-030.6088image
ENSG00000250462.7,LRRC37BP1COADBI.D1870EAG8.6539e-03-0.2625image
chr17:30635215-30637852:+ESCAAZD6244EER8.0363e-04-0.2861image
ENSG00000250462.7,LRRC37BP1ESCABMS.708163EAG5.8539e-04-0.2932image
chr17:30635215-30637852:+GBMCGP.082996EER1.9838e-05-0.3324image
ENSG00000250462.7,LRRC37BP1GBMCGP.082996EAG1.9838e-05-0.3324image
chr17:30635215-30637852:+HNSCAKT.inhibitor.VIIIEER6.9979e-040.2274image
ENSG00000250462.7,LRRC37BP1HNSCAKT.inhibitor.VIIIEAG6.9979e-040.2274image
chr17:30635215-30637852:+KIRCCI.1040EER1.8940e-06-0.2497image
ENSG00000250462.7,LRRC37BP1KIRCCI.1040EAG1.8897e-06-0.2498image
ENSG00000250462.7,LRRC37BP1KIRPAxitinibEAG2.6344e-05-0.2857image
chr17:30635215-30637852:+KIRPCEP.701EER1.4697e-06-0.3259image
chr17:30635215-30637852:+LGGBAY.61.3606EER4.3027e-100.2696image
ENSG00000250462.7,LRRC37BP1LGGBAY.61.3606EAG4.3027e-100.2696image
chr17:30635215-30637852:+LIHCJW.7.52.1EER2.5188e-030.2791image
ENSG00000250462.7,LRRC37BP1LIHCJW.7.52.1EAG2.5188e-030.2791image
chr17:30635215-30637852:+LUADJNK.9LEER5.4574e-03-0.1440image
ENSG00000250462.7,LRRC37BP1LUADJNK.9LEAG5.4654e-03-0.1440image
chr17:30635215-30637852:+LUSCAICAREER2.1303e-03-0.1672image
ENSG00000250462.7,LRRC37BP1LUSCAICAREAG2.2902e-03-0.1661image
ENSG00000250462.7,LRRC37BP1MESOGDC.0449EAG2.5912e-02-0.3088image
chr17:30635215-30637852:+OVBexaroteneEER9.0436e-040.2501image
ENSG00000250462.7,LRRC37BP1OVBexaroteneEAG8.3482e-040.2503image
chr17:30635215-30637852:+PAADBortezomibEER2.8376e-05-0.3929image
ENSG00000250462.7,LRRC37BP1PAADBortezomibEAG2.8376e-05-0.3929image
chr17:30635215-30637852:+PCPGBI.D1870EER9.9636e-040.2844image
ENSG00000250462.7,LRRC37BP1PCPGBI.D1870EAG9.9636e-040.2844image
chr17:30635215-30637852:+PRADGNF.2EER3.1193e-05-0.2006image
ENSG00000250462.7,LRRC37BP1PRADGNF.2EAG2.9959e-05-0.2010image
ENSG00000250462.7,LRRC37BP1READAZD8055EAG2.5561e-05-0.6408image
ENSG00000250462.7,LRRC37BP1SARCAICAREAG1.9010e-03-0.2216image
chr17:30635215-30637852:+SARCAICAREER1.9010e-03-0.2216image
ENSG00000250462.7,LRRC37BP1SKCMCI.1040EAG1.4993e-07-0.2782image
chr17:30635215-30637852:+SKCMCI.1040EER1.4993e-07-0.2782image
chr17:30635215-30637852:+STADBI.D1870EER1.4672e-03-0.2187image
ENSG00000250462.7,LRRC37BP1STADCCT007093EAG1.3551e-030.2218image
ENSG00000250462.7,LRRC37BP1TGCTCGP.082996EAG3.9398e-02-0.2294image
ENSG00000250462.7,LRRC37BP1THCACI.1040EAG2.8176e-08-0.2500image
chr17:30635215-30637852:+THCACI.1040EER2.8176e-08-0.2500image
chr17:30635215-30637852:+THYMABT.263EER2.8357e-080.5183image
ENSG00000250462.7,LRRC37BP1THYMABT.263EAG2.8357e-080.5183image
chr17:30635215-30637852:+UCECDocetaxelEER1.4411e-020.2286image
ENSG00000250462.7,LRRC37BP1UCECDocetaxelEAG1.3447e-020.2299image
chr17:30635215-30637852:+UCSCyclopamineEER1.7824e-03-0.4627image
ENSG00000250462.7,LRRC37BP1UCSCyclopamineEAG1.7824e-03-0.4627image
ENSG00000250462.7,LRRC37BP1UVMCisplatinEAG5.8942e-03-0.5158image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType